JP2025502242A - 水性セビメリン組成物および使用方法 - Google Patents

水性セビメリン組成物および使用方法 Download PDF

Info

Publication number
JP2025502242A
JP2025502242A JP2024541925A JP2024541925A JP2025502242A JP 2025502242 A JP2025502242 A JP 2025502242A JP 2024541925 A JP2024541925 A JP 2024541925A JP 2024541925 A JP2024541925 A JP 2024541925A JP 2025502242 A JP2025502242 A JP 2025502242A
Authority
JP
Japan
Prior art keywords
composition
cevimeline
pharma
dry eye
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502242A5 (enExample
Inventor
ローランド ボッドマイヤー，
チン－ミン チャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheravision Inc
Original Assignee
Biotheravision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheravision Inc filed Critical Biotheravision Inc
Publication of JP2025502242A publication Critical patent/JP2025502242A/ja
Publication of JP2025502242A5 publication Critical patent/JP2025502242A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024541925A 2022-01-25 2023-01-25 水性セビメリン組成物および使用方法 Pending JP2025502242A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2022/013586 2022-01-25
US2022013586 2022-01-25
PCT/US2023/061202 WO2023147318A2 (en) 2022-01-25 2023-01-25 Aqueous cevimeline compositions and methods of use

Publications (2)

Publication Number Publication Date
JP2025502242A true JP2025502242A (ja) 2025-01-24
JP2025502242A5 JP2025502242A5 (enExample) 2026-02-02

Family

ID=87472506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541925A Pending JP2025502242A (ja) 2022-01-25 2023-01-25 水性セビメリン組成物および使用方法

Country Status (4)

Country Link
EP (1) EP4469047A4 (enExample)
JP (1) JP2025502242A (enExample)
TW (1) TWI916635B (enExample)
WO (1) WO2023147318A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO2024016594A1 (es) * 2024-12-02 2024-12-09 Espec Oftalmologicas S A Colirio oftalmológico y/o vehículo farmacéutico indicado para el restablecimiento y la protección de la histéresis de la película lagrimal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2752008T3 (es) * 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
IL265791B (en) 2016-10-04 2022-07-01 Cellix Bio Private Ltd Compositions and methods for the treatment of xerostomia
EP3749303A4 (en) * 2018-02-05 2022-01-26 Cellixbio Private Limited COMBINATION OF AN ANTIMUSCARINE OR ANTICCHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF
US20210369686A1 (en) 2018-10-06 2021-12-02 Biotheravision Llc Ophthalmic preparations of muscarinic agonist and methods of use
BR112021006618B1 (pt) * 2018-10-10 2022-09-27 Presbyopia Therapies, Inc Composições e métodos para o tratamento da presbiopia

Also Published As

Publication number Publication date
WO2023147318A2 (en) 2023-08-03
TWI916635B (zh) 2026-03-01
EP4469047A4 (en) 2026-03-04
WO2023147318A3 (en) 2023-09-21
TW202329958A (zh) 2023-08-01
EP4469047A2 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
AU2003299696B2 (en) Use of rimexolone in the treatment of dry eye
US20080312194A1 (en) Methods and compositions for normalizing meibomian gland secretions
WO2020165839A1 (en) Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile
WO2017066052A1 (en) Formulations and methods for treating high intraocular pressure
JP2026035663A (ja) 高分子量ヒアルロン酸の眼科用薬物輸送ビヒクルとしての使用
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
EP3860600A1 (en) Ophthalmic preparations of muscarinic agonist and methods of use
KR102861273B1 (ko) 산화질소 방출 프로스타미드를 함유하는 안과용 조성물
TWI916635B (zh) 西維美林水溶液組合物和使用方法
Gibson 12 Ophthalmic dosage forms
TWI809317B (zh) 蕈毒鹼性促效劑眼用製劑及其用途
CN121263183A (zh) 吡美莫司用于治疗患者的特征在于牛津分级量表角膜染色评分为4或5分的干眼症的用途
US20210052582A1 (en) Methods of use and pharmaceutical compositions of a selective syk inhibitor
HK1076248B (en) Use of rimexolone in the treatment of dry eye
HK1178446B (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260122